MD‐2 as the Target of a Novel Small Molecule, L6H21, in the Attenuation of LPS‐induced Inflammatory Response and Sepsis
MD‐2 as the Target of a Novel Small Molecule, L6H21, in the Attenuation of LPS‐induced Inflammatory Response and Sepsis
复制标题
DOI：
10.1096/fasebj.29.1_supplement.716.8
复制
发表时间：
2015-04
期刊：
影响因子：
--
通讯作者：
G. Liang;Yi Wang;Gaozhi Chen;Qilu Fang
中科院分区：
文献类型：
--
作者：
G. Liang;Yi Wang;Gaozhi Chen;Qilu Fang
骨髓分化 2 (MD-2) 可识别 TLR4 激活所需的 LPS，并且代表了严重炎症性疾病的有吸引力的治疗靶点。我们之前发现查尔酮衍生物 L6H21 可以抑制 LPS 诱导的巨噬细胞中 TNF-α 和 IL-6 的过度表达。
Myeloid differentiation 2 (MD‐2) recognizes LPS, which is required for TLR4 activation, and represents an attractive therapeutic target for severe inflammatory disorders. We previously found that a chalcone derivative, L6H21, could inhibit LPS‐induced overexpression of TNF‐α and IL‐6 in macrophages.